Browse by author
Lookup NU author(s): Dr Rebecca Kenyon, Professor Andrew Pearson, Professor John LunecORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Previous studies have revealed that the MYCN gene spans approximately 7 kb, while the amplicon has been estimated to be 100 kb to 1 Mb long [1-3]. This implies that several other genes may be present on the MYCN amplicon. Such co-amplified genes could contribute to the malignant phenotype and might provide an explanation for why not all patients with MYCN amplification have a poor outcome. We investigated 7 neuroblastoma cell lines and 167 primary tumours for the co-amplification of candidate genes known to be present near the MYCN locus: ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box protein gene, DDX1. We also investigated further the pG21 expressed sequence previously reported to be co-amplified with MYCN. No co-amplification with the first 3 genes was found in any of the cell lines or tumour samples. DDX1 was found to be amplified along with MYCN in 4/6 (67%) cell lines and 18/38 (47%) of the MYCN amplified tumours. No amplification of DDX1, ODC1, RRM2 or syndecan-1 was found in the absence of MYCN amplification. DDX1 co-amplification was observed to occur mainly in stage 4 or 4S patients. With the exclusion of those with 4S disease, patients with DDX1 co-amplification had a significantly shorter mean (+/-SE) disease-free interval (4.1 +/- 1.4, n = 8 months) compared with patients with MYCN amplification alone (19.6 +/- 4.5, n = 17) (P = 0.04, Welch's unpaired t-test). The pG21 sequence was identical to part of the DDX1 gene. These observations indicate that there is at least 1 other gene co-amplified with MYCN in a proportion of cases and that those patients with DDX1 co-amplification tend to relapse more quickly. It also implies that the MYCN amplicon is of varied size and/or position relative to the MYCN gene. (C) 1997 Elsevier Science Ltd.
Author(s): George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson ADJ, Lunec J
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
Year: 1997
Volume: 33
Issue: 12
Pages: 2037-2042
Print publication date: 01/10/1997
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
Publisher: Pergamon
URL: http://dx.doi.org/10.1016/S0959-8049(97)00206-2
DOI: 10.1016/S0959-8049(97)00206-2
Altmetrics provided by Altmetric
